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Cytochrome P450 oxidoreductase participates in nitric oxide consumption
by rat brain
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In low nanomolar concentrations, NO (nitric oxide) functions
as a transmitter in brain and other tissues, whereas near-micro-
molar NO concentrations are associated with toxicity and cell
death. Control of the NO concentration, therefore, is critical
for proper brain function, but, although its synthesis pathway
is well-characterized, the major route of breakdown of NO in
brain is unclear. Previous observations indicate that brain cells
actively consume NO at a high rate. The mechanism of this
consumption was pursued in the present study. NO consumption
by a preparation of central glial cells was abolished by cell
lysis and recovered by addition of NADPH. NADPH-dependent
consumptionofNOlocalizedtocellmembranesandwasinhibited
by proteinase K, indicating the involvement of a membrane-
bound protein. Puriﬁcation of this activity yielded CYPOR (cyto-
chrome P450 oxidoreductase). Antibodies against CYPOR
inhibited NO consumption by brain membranes and the amount
of CYPOR in several cell types correlated with their rate of NO
consumption. NO was also consumed by puriﬁed CYPOR but
this activity was found to depend on the presence of the vitamin
E analogue Trolox (6-hydroxy-2,5,7,8-tetramethylchromane-2-
carboxylic acid), included in the buffer as a precaution against
inadvertent NO consumption by lipid peroxidation. In contrast,
NOconsumptionbybrainmembraneswasindependentofTrolox.
Hence, it appears that, during the puriﬁcation process, CYPOR
becomes separated from a partner needed for NO consumption.
Cytochrome P450 inhibitors inhibited NO consumption by brain
membranes, making these proteins likely candidates.
Key words: brain, cytochrome P450 oxidoreductase (CYPOR),
NADPH, nitric oxide.
INTRODUCTION
NO (nitric oxide) is an intercellular signalling molecule with a
role in several neurophysiological functions, including the acute
modulation of neuronal excitability, the longer-term synaptic
changes associated with learning, and the development of the
nervous system [1]. Its major physiological receptor is the NOGC
(NO-activated guanylyl cyclase, also known by its homogenate-
based name, soluble guanylyl cyclase), through which it
stimulates the production of the second messenger cGMP. cGMP
has numerous targets, including cyclic nucleotide gated ion
channels, protein kinases and phosphodiesterases, mediating the
short- and long-term modulations of neuronal function [2,3].
These physiological pathways are engaged by low nanomolar
concentrations of NO. The dynamic range of the NOGC receptor,
as measured in intact cells, is between 0.1 and 10 nM NO
[4–6], suggesting that this is the range of NO concentrations
normally experienced by cells. Indeed, electrical stimulation
of cerebellar brain slices yielded 4 nM NO, as measured by
electrodes positioned at the slice surface [7]. Even lower NO
concentrations may also be physiologically relevant, as NO-
dependent phosphorylation events have been reported after
exposure to sub-nanomolar NO concentrations [6].
At higher concentrations, NO may be linked with pathophy-
siology. NO inhibits the respiratory chain enzyme, cytochrome
c oxidase, with an IC50 of 60–120 nM at physiological oxygen
concentrations [4,8], and micromolar NO levels can produce cell
damageviareactionwithsuperoxideandproductionofthehighly
oxidising species peroxynitrite [9].
Control of the amplitude and duration of changes in NO
concentration is therefore likely to critically affect both the
manner in which NO can act physiologically and also whether it
has any pathological effects. The NO concentration experienced
by a cell will be determined by the relative rates of NO
synthesisandbreakdownbut,althoughthemechanismofNOsyn-
thesis from L-arginine is relatively well characterized, there is
no known dedicated consumption pathway for NO in the brain,
although a number of enzymes have been proposed to fulﬁl this
function in other tissues [10–14]. One such protein is CYPOR
(cytochrome P450 oxidoreductase), which is involved in an
extremely avid NO consumption by a colorectal cancer cell line
[15]. A process with similar properties [membrane localization
and NAD(P)H dependence] has also been reported in cultured
endothelial cells [16].
Previous work has revealed that brain tissue actively consumes
NO [17–19]. In dissociated brain cells, part of the NO con-
sumption was found to be caused by lipid peroxidation, which is
likely to be of particular relevance to pathology, but inhibition of
lipid peroxidation unmasked another consumption process [18].
The present study aimed to identify this mechanism.
MATERIALS AND METHODS
All compounds were purchased from Sigma (Poole, U.K.) unless
otherwise stated. All tissue culture media components were
purchased from Invitrogen (Paisley, U.K.).
Abbreviations used: CYPOR, cytochrome P450 oxidoreductase; DETA/NO, diethylenetriamine NONOate; DHEA, dehydroepiandrosterone; DPI,
diphenyleneiodonium chloride; DTPA, diethylenetriaminepentaacetic acid; L-NNA, L-nitroarginine; NO, nitric oxide; NOGC, NO-activated guanylyl cyclase;
NOS, NO synthase; SOD, superoxide dismutase; Trolox, 6-hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid.
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NO measurement
For NO measurements, samples (1 ml) were incubated in an
o p e ns t i r r e dv e s s e la t3 7 ◦C equipped with an NO electrode
(ISO-NOP, World Precision Instruments, Stevenage, U.K.). NO
was delivered using DETA/NO [diethylenetriamine NONOate
(diazeniumdiolate); Alexis Biochemicals, Nottingham, U.K.].
Stock solutions of DETA/NO were prepared in 10 mM NaOH,
kept on ice, and diluted 100-fold or more into the experimental
solution.
Tissue preparation
Animals were killed by decapitation and associated exsanguina-
tion, before removal of the brains, except when blood was taken.
In this case, rats were anaethetised with 5% isoﬂurane in oxygen
at 2 litres/min, and were bled by cardiac puncture before being
killed by cervical dislocation. All procedures were in accordance
with the U.K. Home Ofﬁce guidelines and approved by the local
ethics committee.
Glia
Glial cultures were prepared as described in [18]. Cultures were
used after 6–10 days in vitro at which stage they were fully
conﬂuent. Immunohistochemical staining indicated that 77%
of the cells were astrocytic, 7% neuronal and 16% microglial
(results not shown).
To prepare the suspension of mixed glia for studies of
NO consumption, dishes were washed with ∼100 ml of cell
incubation buffer (20 mM Tris/HCl, 130 mM NaCl, 5 mM KCl,
1.2 mM Na2HPO4 and 11 mM glucose, adjusted to pH 7.45 at
37◦C)andincubatedwith30 mlof0.05%(w/v)trypsin,0.53 mM
EDTAinHBSS(Hanksbalancedsaltsolution)for15 minat37◦C
to dissociate the cells, which were washed and resuspended at
3×10
6 cells/ml in incubation buffer. Cell viability was veriﬁed
at more than 95% based on Trypan Blue staining.
Platelets and white blood cells (used in Figure 2A)
Platelets and white blood cells were prepared from adult
Sprague–Dawley rat blood. Whole blood was collected into acid
citrate dextrose solution (12.5%) and centrifuged at 300 g for
10 min at 20 ◦C. The platelet-rich plasma was removed and the
centrifugation repeated to eliminate residual red and white blood
cells from the supernatant. White cells were aspirated from the
top of the pellet and suspended in platelet buffer containing
137 mMNaCl,0.5 mMMgCl2,0.55 mMNaH2PO4,2.7mMKCl,
25 mM Hepes and 5.6 mM glucose, pH 7.45 at 37 ◦C. The
platelet-rich plasma was then centrifuged for 10 min at 2000 g
at 20◦C and the platelet pellet resuspended in platelet buffer.
Both platelets and white cells were suspended in a small volume,
the protein determined and then each sample was diluted to the
appropriate concentration (usually 1 mg/ml). White cells were
counted using a haemocytometer to determine the relationship
between their number and protein concentration (1 mg/ml protein
corresponded to 48 million white cells/ml).
Synaptosomes
Crude synaptosomes were prepared by homogenizing adult rat
forebrains into 0.25 M sucrose with 8 strokes of a Potter–
Elvehjem homogeniser (Braun Melsungen, Melsungen,
Germany). Homogenates were then centrifuged at 1000 g
for 10 min and the pellet discarded. The supernatant was
spun for a further 15 min at 46000 g and the resulting supernatant
discarded.Thesynaptosomepelletwasresuspendedinincubation
buffer using 8 strokes of the Potter homogenizer.
T47D cells
Control T47D cells and those that had previously been
transfected to overexpress CYPOR [20] were a generous gift
from Kaye Williams (School of Pharmacy and Pharmaceutical
Sciences, University of Manchester, Manchester, U.K.). They
wereculturedinRPMImediumcontaining10%foetalcalfserum,
supplemented with 2 mM glutamine. When conﬂuent, cells were
harvested in the same manner as cultured glia.
Lysates and cell fractionation
Lysates were prepared from the intact suspensions by freezing to
−20◦C, thawing and brief sonication. Lysis was veriﬁed visually
under a light microscope.
Membrane and cytosolic fractions were prepared by centri-
fugation at 53000 rev./min using a TLA-100.2 rotor (Beckman
Instruments)for1 h.Thesupernatantwasretainedandmembranes
were resuspended in incubation buffer by sonication. Protein
concentrations of membranes refer to the concentration of protein
in the pre-spun sample.
Whole brain homogenates and membranes
Membranesfromforebrainsfrom8–12-day-oldSprague–Dawley
rat pups were homogenized in 25 mM Tris/HCl, pH 7.45 using
an Ultraturrax homogenizer. Crude membranes were prepared
by centrifugation of homogenate at 5 mg protein/ml at
53000 rev./min using a TLA-100.2 rotor for 1 h. To prepare
a purer preparation, homogenates were centrifuged for 1 h
at 50000 g, the supernatant discarded and the membranes
resuspended and centrifuged for a further 1 h at 50000 g,b e f o r e
ﬁnal resuspension in 25 mM Tris/HCl, pH 7.45, at ∼10 mg/ml
protein.Thisdualspinwasfoundtoincreasetherecoveredactivity
more than the single 53000 rev./min (using a TLA-100.2 rotor)
spin (results not shown). Membranes were then stored at −80◦C
for later use.
Solubilization and chromatography
Forebrain membranes (0.8 mg/ml protein) were solubilized by
gentle agitation for 1 h at 4◦C in buffer containing 25 mM
Tris/HCl, pH 7.45, 100 mM KCl, 10% (v/v) glycerol and
3 mM dodecyl maltoside (Calbiochem, Nottingham, U.K.). Any
remaining particulate material was removed by centrifugation at
53000 rev./minusingaTLA-100.2rotorfor1 h.Chromatography
was conducted using the ¨ AKTA FPLC system (GE Healthcare
UK, Amersham, Bucks. U.K., who also provided all the columns
used). Fast ﬂow Q cationic ion exchange columns were used for
the initial capture step. Solubilized membranes (150 ml) were
loaded onto 4×5 ml columns and the protein was eluted with a
gradient of 100–500 mM KCl over 200 min, with a ﬂow rate of
1 ml/min. The fractions that showed the most NADPH-dependent
NO consumption were combined and desalted into 100 mM KCl
(4×5 ml Hi Trap columns at a ﬂow rate of 1–1.3 ml/min), then
loaded onto a Mini Q cationic ion-exchange column, before
elution with a further 100–500 mM KCl gradient over 2 h, with a
ﬂow rate of 0.2 ml/min. The most active fractions were combined
and 1 ml was loaded on a Superdex 200 gel ﬁltration column and
eluted with a ﬂow rate of 0.25 ml/min. The molecular mass eluted
at each volume of eluate from the Superdex 200 column was
calibrated according to standards (BioRad, Hemel Hempstead,
U.K.).Samplesfromeachfraction wereconcentratedbyspinning
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through a 5 kDa cut-off ﬁlter (Ultrafree-MC, Millipore, MA,
U.S.A.), boiled for 10 min with SDS and separated using gel
electrophoresis (45 min at 200 V on 4–15% Ready Gel Tris-HCl
gels;BioRadLaboratories)beforestainingusingColloidalBlueor
silver stain. Colloidal Blue-labelled bands were excised and sent
for protein identiﬁcation (York Proteomics Services, University
of York, U.K.).
Quantiﬁcation of CYPOR activity
The rate of cytochrome c reduction is an indicator of CYPOR
activity [21]. Cytochrome c reduction was followed by measur-
ing absorbance at 550 nm every 10–12 s for 10 min after
addition of 100 μM NADPH to a reaction mix containing cell
membranes, 37 μM cytochrome c, 100 μM sodium cyanide
(NaCN; to block any cytochrome oxidase activity), 100 μM
DTPA (diethylenetriaminepentaacetic acid), 100 μMT r o l o x
(6-hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid; not
included in some cases) and 1000 units/ml SOD (superoxide
dismutase), in 25 mM Tris/HCl buffer or cell incubation
buffer. The CYPOR activity of membranes was determined by
comparison to the rate of cytochrome c reduction by puriﬁed
CYPOR standards (Sigma).
Experiments were carried out in the presence of 1000 units/ml
SOD and 100 μM DTPA (intact and lysed glia) and also 100 μM
Trolox (all experiments, unless otherwise stated) to block any
lipid peroxidation. Protein concentrations were determined by
the bicinchoninic acid method.
Statistics
Unlessotherwisestated,datarepresentmeans+ −S.E.M.Statistical
analyses were carried out using SPSS for Windows 11.5 (SPSS
U.K., Woking, U.K.).
RESULTS
Intact cerebellar glia inactivate NO
The NO-consuming activity of brain tissue was assessed by
comparing the NO concentration proﬁle in control buffer and
various preparations of brain tissue on application of the NO
donor DETA/NO. Since this compound releases NO with a half-
life of 20.5 h, the rate of release is essentially constant over the
time-course of these experiments. The NO concentration initially
rises but reaches a steady concentration when the rate of release
equals the rate of breakdown. In control buffer, NO is consumed
byreactionwithO2 (autoxidation;[22]),butinthepresenceofglia
cultured from the cerebellum, NO reached a lower steady-state
concentration, signifying faster consumption (Figure 1A; [18]).
Pharmacological inhibitors of previously proposed breakdown
pathways for NO were used to try to identify the consumption
process in cerebellar glia. NOS (NO synthase) inhibition
using L-NNA (L-nitroarginine; 100 μM) had no effect on NO
consumption (control NO plateau following 250 μMD E T A /
NO=208+ −37 nM, plus L-NNA=166+ −28 nM; P=0.37 using
Student’s t test), nor did the prostaglandin H synthase inhibitor
indomethacin(controlNO=211+ −21 nM;20 μMindomethacin,
NO=226+ −19 nM; P =0.90 using Student’s t test). The
standard inclusion of 1000 units/ml SOD in the reaction mix
rules out a contribution of reaction with superoxide (doubling the
concentration to 2000 units/ml had no additional effect; results
not shown). The vitamin E analogue Trolox (100 μM), which
was included throughout to inhibit inadvertent lipid peroxidation,
alsoinhibitslipoxygenases[23],therebyrulingouttheseenzymes
as well.
NO inactivation depends on a membrane-bound ﬂavoprotein
The consumption of NO by cerebellar glia was inhibited by
DPI(diphenyleneiodoniumchloride),aninhibitorofﬂavoproteins
(Figure 1A, steady-state after 100 μM DETA/NO: control
cells=105+ −8n M ; 0 . 5μMD P I =192+ −15 nM; P=0.007
using Student’s t test, n=3).
Inhibition of NADPH synthesis by 100 μM DHEA (dehy-
droepiandrosterone; which typically reduces intracellular
NADPH levels by less than half [24,25]) also produced a
signiﬁcant decrease in the NO-consuming activity of intact glia
(control plateau after 100 μM DETA/NO=106+ −6 nM; plus
DHEA=141+ −6n M ; P =0.011, Student’s t test, n=3). NO
consumption by the glia was destroyed by cell lysis but could be
recovered by addition of 100 μM NADPH (Figures 1B and 1C),
suggesting the same process is responsible for NO consumption
in both intact and lysed glia.
NADPH-dependent NO consumption localized to the mem-
brane fraction following high-speed centrifugation of lysed glia
(Figures 1B and 1C). Membranes from forebrain synaptosomes
and whole brain homogenates also both exhibited a similar
NADPH-dependent NO consumption (Figure 1D). As in intact
glia, this NADPH-dependent NO consumption could be inhibited
by DPI (Figure 2D). Incubation of synaptosome or glial
membranes with proteinase K degraded all protein and abolished
NADPH-dependent NO consumption (Figure 1E), indicating that
a protein is required. It seems, therefore, that brain membranes
possess a ﬂavin-dependent protein that is involved in NO
consumption.
Solubilization of brain membranes with 3 mM dodecylmaltos-
ide preserved NADPH-dependent NO consumption (but see
below), allowing puriﬁcation of this activity by chromatography
(see the Materials and methods section). Two major protein
productswereidentiﬁedafterthreepuriﬁcationsteps:thecalcium-
binding protein calnexin and the NADPH-dependent ﬂavoprotein
CYPOR (Supplementary Figure S1 at http://www.BiochemJ.
org/bj/419/bj4190411add.htm). The NADPH-binding properties
of CYPOR made it a good candidate for mediating NADPH-
dependentNOconsumptionbybrainmembranes.IndeedCYPOR
has already been implicated in the extremely avid NAD(P)H-
dependent NO consumption in a colorectal cancer cell line [15].
Cytochrome P450 oxidoreductase content correlates with NO
consumption activity
We quantiﬁed the CYPOR activity in membranes of glia, whole
brain, and several other cell types, by measuring the rate of
reduction of cytochrome c. The CYPOR content of the different
cell types correlated with the NO consumption activity, expressed
as the change in NO on application of NADPH as a percentage
of the NO plateau after DETA/NO addition (Figure 2A). Cell
types previously found to have no detectable NO-consuming
activity when intact (platelets and white blood cells; [18])
also showed no NADPH-dependent NO consumption by their
membranes, and had a low CYPOR content. A breast cancer cell
line (T47D) showed some NO consumption when intact, even at
a very low cell density (0.06 mg/ml protein; plateau NO=82%
of that in buffer, P=0.018 compared with buffer, n=6), and also
demonstrated NADPH-dependent membrane consumption and
some CYPOR content (Figure 2A). NO consumption by intact
T47D cells and by their membranes was higher when CYPOR
wasconstitutivelyoverexpressed(Figure2A;plateauNOinintact
cells=43% of buffer, P<0.0001 compared with buffer, n=6).
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Figure 1 NO inactivation by glia requires NADPH and is dependent on a membrane protein
(A) Typical NO proﬁles on addition of 100μM DETA/NO to buffer alone or 1 mg/ml cultured cerebellar glia + −0.5μMD P I .( B) Representative traces of NO accumulation following sequential
applications of 100μM DETA/NO (at t =0) and 100μM NADPH (open arrows) to buffer, glial lysate and, following centrifugation at 53000rev./min using a TLA-100.2 rotor for 1h, cytosolic
supernatantplusmembranepellet,themembranepelletandsupernatantalone.LysedcellsonlyinactivateNOafteradditionofNADPH.Thisactivityremainsinthepelletafterhigh-speedcentrifugation.
(C) Summary of results from (B). Buffer and cytosol are not signiﬁcantly different from each other, but were different from the membrane pellet, resuspended lysate and control lysate (repeated
measuresusingANOVAwithTukeyposthoc tests,P <0.001;n=4).(D)Summaryofresultswhen100μMDETA/NOand100μMNADPHwereaddedtomembranesfromglia,synaptosomesand
whole brain (all at 1mg/ml). Results are normalized to the NO concentration reached on each experimental day when 100μM DETA/NO was added to buffer alone (n=4). (E) NO levels following
addition of 100μM DETA/NO and 100μM NADPH to synaptosome and glial membranes at 1 mg of protein/ml before and after incubation at 37◦C for 30min+ −0.5mg/ml proteinase K. NADPH
decreased NOlevels in controlsbutnotin proteinaseK-treated membranes(P =0.20;glial membranes:n=8; synaptosomemembranesn=3).Theincubationat 37◦C hascausedsomedecrease
in the activity of the controls compared with that observed in (C).
Anti-CYPOR antibodies inhibit NO consumption by brain
membranes
Inhibition of CYPOR activity in brain membranes was achieved
by incubation of brain membranes (1 mg protein/ml) with an
antibody against CYPOR (α-CYPOR, Abcam, Cambridge, U.K.;
0.33 or 1 mg/ml) for 2 h on ice. Unlike after incubation with
1 mg/ml of control γ-immunoglobulins or buffer alone, both
antibody concentrations dramatically reduced the activity of
CYPOR, as assessed by the ability of brain membranes to reduce
cytochrome c (Figure 2B). Similarly, NADPH-dependent NO
consumption was reduced by incubation with 0.33 mg/ml α-
CYPOR, but not by γ-immunoglobulins or buffer (Figure 2C),
indicatingthatNOconsumptionbybrainmembranesisdependent
on CYPOR activity. The degree of inhibition by α-CYPOR
was similar to that produced by DPI (Figures 2C and 2D),
as would be expected if both are targeting the same protein
(CYPOR).
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Figure 2 NADPH-dependent NO consumption involves CYPOR
(A)300μMDETA/NOwasaddedtomembranesfromdifferentcelltypes(aslabelled)incellincubationbuffer,withDTPAbutnoTrolox.1Bufferalone;2,T47Dwild-typecells(0.05mgofprotein/ml);
3, white blood cells (2mg of protein/ml); 4, platelets (2 mg of protein/ml); 5, crude brain (0.5mg protein/ml); 6, partially puriﬁed brain (0.42mg protein/m); 7, glia (1mg of protein/ml); 8, T47D
transfected cells (0.05mg of protein/ml). Note that the experiment with T47D wild-type and transfected cells was carried out on two separate occasions, so there are duplicates of the data from these
cell types. The change in NO level on subsequent addition of NADPH was plotted against CYPOR content. CYPOR content signiﬁcantly correlates with NO consumption (Pearson’s r =0.85, which
is signiﬁcantly different from zero; P =0.002, n=3–6). (B) To assay cytochrome c reduction by CYPOR, absorbance at 550nm was followed with time. After incubation for 2h on ice with buffer
(closed circles), absorbance increased linearly. The rate was only slightly slower when incubated with 1 mg/ml IgG (open triangles), but was greatly reduced by incubation with 0.33 or 1mg/ml of a
CYPOR antibody (ﬁlled triangles and open circles, respectively). (C) NO concentration reached after 100μM DETA/NO addition to brain membranes at 1 mg of protein/ml, following incubation for
2 h on ice with control buffer, 0.33mg/ml of γ-IgG or 0.33mg/ml of α-CYPOR, before (open bars) and after (solid bars) addition of 100 μM NADPH. The change in NO on NADPH addition was
signiﬁcantly less following incubation with α-CYPOR (one-way ANOVA with Tukey post-hoc tests; P <0.001 compared with buffer and IgG; n=4), but was not affected by incubation with γ-IgG
(P >0.05 compared with buffer). (D) NO concentration reached after sequential additions of 100μM DETA/NO, 100μM NADPH and 50μM DPI to synaptosome membranes (1mg protein/ml).
DPI signiﬁcantly inhibits NADPH-dependent NO consumption (one-way ANOVA with Tukey post-hoc tests: NADPH compared with DPI, P <0.01; DPI compared with DETA/NO, P >0.05; n=
6).DPIandα-CYPORinhibittheNADPHeffecttothesameextent(Student’st test:100μMDETA/NOplus100μMNADPHplus50μMDPIcomparedwith100μMDETA/NOplus100μMNADPH
plus 0.33mg/ml of α-CYPOR; P =0.41, n=4–6).
CYPOR requires a partner to consume NO
A sC Y P O Rs e e m st ob ei n v o l v e di nN Oc o n s u m p t i o nb yb r a i n
membranes, we tested whether puriﬁed CYPOR could also
consume NO in an NADPH-dependent manner. In contrast with
brain membranes, puriﬁed CYPOR did not consume NO upon
addition of NADPH, unless Trolox and DTPA (100 μM) were
present in the reaction mix (Figure 3A). Further study revealed
that the critical component was Trolox, which concentration-
dependently enabled NO consumption by puriﬁed CYPOR,
whereas DTPA did not (Figures 3B and 3C). Other antioxidants,
edaravone (500 μM) and phenothiazine (200 μM), could not
sustain NO consumption by CYPOR (results not shown),
indicating that this is a special property of Trolox rather than
a general antioxidant effect.
Solubilization of brain membranes by incubation with the de-
tergent dodecylmaltoside (3 mM), 100 mM KCl and 10% (w/v)
glycerol reduced NADPH-dependent NO consumption but this
could be recovered by addition of Trolox (change in NO concen-
tration on addition of 100 μM NADPH to 300 μM DETA/NO
without Trolox=38+ −13 nM, with Trolox=89+ −8n M ; S t u -
dent’s t test: P=0.03, n=3). Solubilized membranes in the
presence of Trolox could then be further puriﬁed to yield puriﬁed
CYPOR, as described above. This suggests that the solubilization
process may physically separate CYPOR from a partner which
is also involved in NADPH-dependent NO consumption and for
which Trolox can substitute.
A major role of CYPOR is to maintain cytochrome P450s
in the reduced state. We tested two well-known cytochrome
P450 inhibitors with distinct inhibitory proﬁles towards subtypes
of this enzyme family, namely clotrimazole and ketaconzole
[26]. The compounds (200 μM) did not affect CYPOR activity
in the presence of Trolox (results not shown) but they
both concentration-dependently reduced NADPH-dependent NO
consumption by brain membranes (Figure 3D), suggesting that
one or more cytochrome P450s may be involved.
DISCUSSION
In this study we present evidence that brain cells consume NO by
a membrane-localized process that involves NADPH oxidation
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Figure 3 CYPOR requires a partner to inactivate NO
(A) Plateau NO concentrations following application of NADPH to 300μM DETA/NO and puriﬁed CYPOR (100 m-units/ml) or brain membranes (2mg of protein/ml)+ −DTPA and Trolox (both
100μM). In the case of puriﬁed CYPOR, NADPH reduced the NO concentration (and therefore increased NO consumption) only when DTPA and Trolox were present, whereas DTPA and Trolox had
no effect on NADPH-dependent NO consumption by brain membranes. n=4. (B) Example traces showing the NO proﬁle when 300μM DETA/NO was added to 100 m-units/ml puriﬁed CYPOR.
Trolox, but not DTPA (both 100μM), was required for NADPH-dependent NO consumption. (C) The effect of 100μM NADPH addition to 300μM DETA/NO+ −100 m-units/ml CYPOR and NADPH
plus different Trolox concentrations. A logistic ﬁt to the data (continuous line) gives an EC50 for Trolox of 270μM. n=4. (D) The decrease in NO concentration on the addition of NADPH to brain
membranes (2mg/ml) plus 300μM DETA/NO was reduced by the cytochrome P450 inhibitors clotrimazole (squares) and ketaconazole (circles). IC50 values were calculated from logistic ﬁts to the
data (solid lines). n=4.
by CYPOR, a microsomal protein that transfers electrons
from NADPH to an acceptor, classically a haem-containing
cytochrome P450 [27]. Cytochrome P450 inhibitors decreased
NO consumption by brain membranes, suggesting that reduction
of these proteins by CYPOR underlies NO consumption.
Cytochrome P450s perform hydroxylation reactions which,
in the brain, are involved in diverse functions including
steroidhormonesynthesis,cholesterolhomoeostasisandvitamin,
eicosanoid and xenobiotic metabolism [28,29]. Both CYPOR and
several members of the cytochrome P450 family are expressed
in brain, though at much lower levels than in the liver (1–10%;
[30]).Interestingly,NOhasbeenshowntobindandinhibitseveral
cytochrome P450s [31,32], making them intriguing candidates
for NO consumption by brain membranes. Indeed, the reductase
domain of NOS is very similar to that of CYPOR and performs
an analogous function, donating electrons to the haem-containing
oxygenase domain [27]. NO binding to the NOS haem domain
inhibits its catalytic activity and NO can then be consumed here
by reaction with O2 [33].
The CYPOR/cytochrome P450 system has been previously
linked with NO consumption in a colorectal cancer cell line
(CaCo-2 cells; Hallstrom et al. [15]) in which the authors
suggest one of the following reaction schemes: 1) NO binding to
cytochrome P450 haem-Fe
2+ to form Fe
2+-NO, which reacts with
O2 to form nitrate and haem-Fe
3+,o r2 )O 2 binding to the same
haem-Fe





a similar NADPH/CYPOR-dependent NO consumption process
suggests that this general mechanism plays a role in normal (non-
cancer) cells.
The sensitivity of brain membranes to imidazole-derived
cytochrome P450 inhibitors suggests that the operative cyto-
chrome P450 is not likely to be CYPs 3A4, 2A6 or 2C19, which
are much more sensitive to ketaconazole and clotrimazole [26].
The inhibition proﬁles found here are instead similar to those
for CYP2D6 or CYP1A2 which are less sensitive to imidazole
inhibition and are both expressed in the brain [26,34,35]. On a
cautionary note, however, both clotrimazole and ketoconazole
may affect proteins other than cytochrome P450s (e.g. K
+
channels; [36]).
As CYPOR was able to consume NO in the presence of the
soluble vitamin E analogue Trolox (but not other antioxidants), it
isalsopossiblethatvitaminEisanadditionalendogenouspartner
forCYPORinbrainmembranes.VitaminEishighlylipid-soluble
and its membrane location would be appropriate for interacting
with CYPOR, a membrane protein. Unfortunately, the high lipid
solubility of vitamin E makes it very difﬁcult to explicitly test for
this relationship. Attempts to incorporate vitamin E and CYPOR
into brain membranes and reconstituted phospholipid vesicles
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Table 1 Rate constants for NO consumption by brain tissue
The rate of NO consumption at steady-state is equal to the rate of NO release from DETA/NO and is therefore given by the equation:
Rate of NO consumption = 1.6 × [DETA/NO] ×
In2
t1/2 .
The stoichiometry of NO release from DETA/NO is 1.6, as measured in this laboratory [19] and t1/2 is the half-life of DETA/NO (20.5h at 37◦C). The mean rate constant is 0.59+ −0.06min−1 per
mg of protein.
DETA/NO Rate of NO Tissue Steady state NO Rate constant for NO consumption
Figure concentration (μM) consumption (μM/min) concentration (mg/ml) concentration (μM) (min−1 per mg of protein)
1(C) 100 0.09 1 0.12 0.75
2(C) 100 0.09 1 0.19 0.47
2(D) 100 0.09 1 0.17 0.53
3(A) 300 0.27 2 0.23 0.59
were not effective in enhancing NO consumption activity (results
not shown), but we were unable to positively control for their
successful incorporation, so cannot exclude a role for vitamin
E. Endogenous vitamin E levels can be manipulated by dietary
means, but this procedure also affects levels of cytochrome P450s
and other proteins [37], so would not clarify the issue.
The mechanism by which Trolox, CYPOR and NADPH
together support NO consumption is unclear. Flavins in the nitric
oxidesynthasereductasedomain(whichisanalogoustoCYPOR)
can pass electrons to molecular O2 to produce superoxide [38].
In the bulk solution this will be dismutated by SOD to hydrogen
peroxide but it is possible that at the active site, NO could react
with superoxide to form peroxynitrite, a very reactive molecule
that could oxidize the protein structure. Possibly Trolox could
then recover enzymatic activity by reducing the relevant residues.
Alternatively, Trolox can be oxidized to a quinone in the presence
of hydrogen peroxide [39], produced by SOD, and Trolox–
quinone can then be reduced by NADPH to a semiquinone which
readily reduces molecular oxygen to superoxide [40]. As above,
superoxide could react directly with NO or alternatively, NO
itself may be directly reduced by quinones or ﬂavins. Which,
if any, of these mechanisms underlies the Trolox-dependent NO
consumption remains unclear. Before pursuing it further, the
physiological relevance of this process to that observed in brain
membranes and intact cells needs to be clariﬁed, bearing in mind
that the lack of Trolox-dependence in brain membranes indi-
cates that the Trolox effect may be an artifact.
NADPH-dependent NO consumption in brain is somewhat
less active than in CaCo-2 cells. In the latter, the rate of NO
consumption at 1 μM NO was 4 nmol/min per mg of protein,
or 4 μM/min at 1 mg of protein/ml. In brain membranes, the rate
constantforNOconsumptionis0.59min
− 1 permgofprotein(see
Table 1 and calculations in the legend), so at 1 mg of protein/ml
and 1 μM NO, the rate of NO consumption is 0.59 μM/min,
almost 7-fold lower than in CaCo-2 cells. That CaCo-2 cells are
more active than brain is consistent with the relative expression
levelsoftheCYPOR/cytochromeP450systems:lowinbrain[30]
but relatively high in the gastrointestinal tract [41] and in cancer
cells and cell lines [42,43]. This pattern is consistent with the
results showing a correlation between CYPOR activity and NO
consumption in different cell types (Figure 2A).
In conclusion, CYPOR-dependent NO consumption appears
important in shaping the NO concentration in both brain homo-
genates and intact brain cells. An additional component, possibly
a cytochrome P450-like protein or a vitamin E-like compound,
also appears to be needed. The absence of an effect of DPI
on cGMP levels and, by extension, NO levels in slices of rat
cerebellum [44] may suggest a limited role for this process in
intact cerebellum. However, seeing that the NADPH-dependent
responses in cerebellar glia are smaller than in forebrain
synaptosomes (see Figures 1C and 1D), regional or cellular dif-
ferencesmayexist.Examinationofthispossibilityandmoredirect
measurement of NO levels within intact brain tissue are needed
to clarify the role of the NO inactivation pathway in vivo.
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Cytochrome P450 oxidoreductase participates in nitric oxide consumption
by rat brain
Catherine N. HALL1,2, Robert G. KEYNES1 and John GARTHWAITE
Wolfson Institute for Biomedical Research, University College London, Gower Street, London WC1E 6BT, U.K.
Figure S1 Puriﬁcation of NADPH-dependent NO consumption
(A)ChromatogramshowingelutionofproteinfromaSuperdex-200gelﬁltrationcolumn(broken
line) and NADPH-dependent NO consumption of samples at different volumes of elution (black
bars). The second protein peak is the only one that is active. (B) Silver-stained gel showing
proteinsizemarkers(M;withvaluesinkDatotheleft)andconcentratedsample(S),whicheluted
from the Superdex-200 column at 12ml. When stained with Colloidal Blue, only the labelled
band at ∼80kDa was apparent. This was excised and, using peptide mass ﬁngerprinting and
combined MALDI (matrix-assisted laser-desorption ionization)-MS and MS/MS (tandem MS)
analysis (York Proteomics Services, University of York, U.K.), was found to contain calnexin
(65kDa) and CYPOR (76kDa).
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